$HIPH - News Out - Breaking News – DEA Removes CBD as a Schedule 1 Drug. CBD Stocks to Watch - GW Pharma, India Globalization Capital, Inc., Tilray Inc, American Premium Water Corp

POINT ROBERTS, Wash., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Investorideas.com, a global news source covering leading equity sectors, including marijuana and hemp, releases an industry snapshot focusing on companies in the CBD space following its recent removal as a Schedule 1 drug.

Why all the excitement about CBD? “CBD is growing faster than cannabis in the U.S. and will soon be a $22 billion industry. It’s been flying under the radar but is set to explode having profound impacts on CPG and Pharma” says industry expert, Brightfield Group. https://www.brightfieldgroup.com/.

It’s impact on pharmaceutical industry was all the buzz last week following news that the DEA has approved Epidiolex, an epilepsy drug created by GW Pharmaceuticals, as a Schedule V controlled substance. Epidiolex is an oral solution that contains cannabidiol (CBD) extracted from the cannabis plant. This is the first FDA-approved drug made from the cannabis plant.

The September 28th notice from the Drug Enforcement Administration, Department of Justice said, “With the issuance of this final order, the Acting Administrator of the Drug Enforcement Administration places certain drug products that have been approved by the Food and Drug Administration (FDA) and which contain cannabidiol (CBD) in schedule V of the Controlled Substances Act (CSA). Specifically, this order places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in schedule V.”

This news sent several CBD stocks moving to the upside including Tilray Inc, also making inroads into Pharma. On September 18th the company announced that “the U.S. Drug Enforcement Administration (DEA) has granted approval to import a cannabinoid study drug into the United States from Canada for a clinical trial at the University of California San Diego (UC San Diego) Center for Medicinal Cannabis Research (CMCR) examining its safety, tolerability and efficacy for Essential Tremor (ET).”

The news also went on to say, “Tilray is providing a cannabinoid formulation for the trial in capsule form, which will allow researchers to test an investigational drug product containing two active ingredients extracted from the cannabis plant, cannabidiol (CBD) and tetrahydrocannabinol (THC). Dr. Fatta Nahab, a board-certified neurologist and director of the Functional Imaging of Neurodegenerative Disorders Lab at the UC San Diego Health’s Movement Disorder Center, will serve as the principal investigator for the study. It is expected to begin in early 2019 with financial support from Tilray and the International Essential Tremor Foundation.”

Investors have also been betting and winning on the successful marriage of CBD in the beverage market. Stocks like Aurora Cannabis Inc. and India Globalization Capital, Inc. have given investors big wins, with Aurora skyrocketing on a potential Coca Cola deal and IGC (NYSE: IGC) soaring on news that it “plans to create a branded, hemp/CBD-infused version of the formulation that addresses market demand for energy drinks with the inclusion of healthy properties derived from hemp including CBD.” India Globalization Capital stock traded over 100 Million shares on Friday and was up over 40%.

For investors wanting a taste of the CBD opportunity but looking for a more inexpensive way to get into the market, Ryan Fishoff, CEO of American Premium Water Corporation (OTC: HIPH) says he is growing his CBD beverage company and “Positioning for Fourth Quarter M&A Activity.” According to the news, “the Company has identified four targets, three within the CBD/THC sector, and is currently engaged in active negotiations.” This is building on its current market entry and news that the company officially launched its LALPINA Hydro CBD product for sale on its website (www.lalpinawater.com) on August 27th. Mr. Fishoff also noted, “The Company’s goal is to file a Form-10 for uplisting by the end of the year.”

Looking at the company’s CBD products, SeeThruEquity coverage on American Premium Water with a target price of $0.15 reported, “LALPINA Hydrogen CBD positions the company to tap into growing consumer interest around CBD related products as this is the only known Hydrogen CBD water in the market. There is a large market opportunity given the growing number of cannabis dispensaries which could be potential customers.”